Can-Fite submits Phase 2 Piclidenoson trial protocol in rare genetic disorder Lowe syndrome

• Can-Fite launched its first clinical program testing Piclidenoson in Lowe syndrome, a rare inherited disorder with no approved disease-modifying treatments.
• Results have not been presented; the Phase 2 trial is planned to run for six months.
• The open-label, single-center study will treat 5 adults twice daily to assess whether kidney function shows meaningful improvement.
• Positive findings are intended to support regulatory discussions and could shape a potential registration path for the drug in this indication.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Can Fite Biofpharma Ltd. published the original content used to generate this news brief on August 03, 2026, and is solely responsible for the information contained therein.